Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer
Abstract Purpose We conducted a retrospective analysis of the data of patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) to investigate the associations between clinical factors and the overall survival. Methods We retrieved the patient data from the medi...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2022-03-01
|
| Series: | The Egyptian Journal of Bronchology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43168-022-00121-1 |
| _version_ | 1811331903340412928 |
|---|---|
| author | Minehiko Inomata Masahiro Matsumoto Isami Mizushima Kana Hayashi Zenta Seto Kotaro Tokui Chihiro Taka Seisuke Okazawa Kenta Kambara Shingo Imanishi Toshiro Miwa Ryuji Hayashi Shoko Matsui Kazuyuki Tobe |
| author_facet | Minehiko Inomata Masahiro Matsumoto Isami Mizushima Kana Hayashi Zenta Seto Kotaro Tokui Chihiro Taka Seisuke Okazawa Kenta Kambara Shingo Imanishi Toshiro Miwa Ryuji Hayashi Shoko Matsui Kazuyuki Tobe |
| author_sort | Minehiko Inomata |
| collection | DOAJ |
| description | Abstract Purpose We conducted a retrospective analysis of the data of patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) to investigate the associations between clinical factors and the overall survival. Methods We retrieved the patient data from the medical charts. Patients who were diagnosed as having EGFR-mutant NSCLC and treated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) between 2007 and 2020 at our institution were included in the analysis. Results A total of 130 patients were included in the analysis. A log-rank test identified EGFR exon 19 deletion in the tumor, an Eastern Cooperative Oncology Group performance status of 0–1, serum lactate dehydrogenase level, local therapy for brain metastasis, and sequential osimertinib therapy for patients with the T790M mutation acquired after primary EGFR-TKI therapy as being significantly associated with a better overall survival. Analysis using a Cox proportional hazards model identified EGFR exon 19 deletion in the tumor, an Eastern Cooperative Oncology Group performance status of 0–1, serum lactate dehydrogenase level, local therapy for brain metastasis, and sequential therapy with osimertinib as being independently associated with a prolonged overall survival. Conclusion Our analysis suggested that EGFR mutation status, an Eastern Cooperative Oncology Group performance status, serum lactate dehydrogenase level, local therapy for brain metastasis, and sequential therapy with osimertinib were associated with overall survival in patients with EGFR-mutant NSCLC in clinical practice settings. |
| first_indexed | 2024-04-13T16:28:51Z |
| format | Article |
| id | doaj.art-8f2fac69bfef4d0bbfcfa51ee111cb99 |
| institution | Directory Open Access Journal |
| issn | 1687-8426 2314-8551 |
| language | English |
| last_indexed | 2024-04-13T16:28:51Z |
| publishDate | 2022-03-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | The Egyptian Journal of Bronchology |
| spelling | doaj.art-8f2fac69bfef4d0bbfcfa51ee111cb992022-12-22T02:39:40ZengSpringerOpenThe Egyptian Journal of Bronchology1687-84262314-85512022-03-011611710.1186/s43168-022-00121-1Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancerMinehiko Inomata0Masahiro Matsumoto1Isami Mizushima2Kana Hayashi3Zenta Seto4Kotaro Tokui5Chihiro Taka6Seisuke Okazawa7Kenta Kambara8Shingo Imanishi9Toshiro Miwa10Ryuji Hayashi11Shoko Matsui12Kazuyuki Tobe13First Department of Internal Medicine, Toyama University HospitalFirst Department of Internal Medicine, Toyama University HospitalFirst Department of Internal Medicine, Toyama University HospitalFirst Department of Internal Medicine, Toyama University HospitalFirst Department of Internal Medicine, Toyama University HospitalFirst Department of Internal Medicine, Toyama University HospitalFirst Department of Internal Medicine, Toyama University HospitalFirst Department of Internal Medicine, Toyama University HospitalFirst Department of Internal Medicine, Toyama University HospitalFirst Department of Internal Medicine, Toyama University HospitalFirst Department of Internal Medicine, Toyama University HospitalDepartment of Medical Oncology, Toyama University HospitalFirst Department of Internal Medicine, Toyama University HospitalFirst Department of Internal Medicine, Toyama University HospitalAbstract Purpose We conducted a retrospective analysis of the data of patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) to investigate the associations between clinical factors and the overall survival. Methods We retrieved the patient data from the medical charts. Patients who were diagnosed as having EGFR-mutant NSCLC and treated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) between 2007 and 2020 at our institution were included in the analysis. Results A total of 130 patients were included in the analysis. A log-rank test identified EGFR exon 19 deletion in the tumor, an Eastern Cooperative Oncology Group performance status of 0–1, serum lactate dehydrogenase level, local therapy for brain metastasis, and sequential osimertinib therapy for patients with the T790M mutation acquired after primary EGFR-TKI therapy as being significantly associated with a better overall survival. Analysis using a Cox proportional hazards model identified EGFR exon 19 deletion in the tumor, an Eastern Cooperative Oncology Group performance status of 0–1, serum lactate dehydrogenase level, local therapy for brain metastasis, and sequential therapy with osimertinib as being independently associated with a prolonged overall survival. Conclusion Our analysis suggested that EGFR mutation status, an Eastern Cooperative Oncology Group performance status, serum lactate dehydrogenase level, local therapy for brain metastasis, and sequential therapy with osimertinib were associated with overall survival in patients with EGFR-mutant NSCLC in clinical practice settings.https://doi.org/10.1186/s43168-022-00121-1Epidermal growth factor receptorTyrosine kinase inhibitorLung cancerOsimertinibSurvivalPrognosis |
| spellingShingle | Minehiko Inomata Masahiro Matsumoto Isami Mizushima Kana Hayashi Zenta Seto Kotaro Tokui Chihiro Taka Seisuke Okazawa Kenta Kambara Shingo Imanishi Toshiro Miwa Ryuji Hayashi Shoko Matsui Kazuyuki Tobe Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer The Egyptian Journal of Bronchology Epidermal growth factor receptor Tyrosine kinase inhibitor Lung cancer Osimertinib Survival Prognosis |
| title | Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer |
| title_full | Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer |
| title_fullStr | Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer |
| title_full_unstemmed | Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer |
| title_short | Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer |
| title_sort | impact of sequential therapy with osimertinib on the overall survival in patients with egfr mutant non small cell lung cancer |
| topic | Epidermal growth factor receptor Tyrosine kinase inhibitor Lung cancer Osimertinib Survival Prognosis |
| url | https://doi.org/10.1186/s43168-022-00121-1 |
| work_keys_str_mv | AT minehikoinomata impactofsequentialtherapywithosimertinibontheoverallsurvivalinpatientswithegfrmutantnonsmallcelllungcancer AT masahiromatsumoto impactofsequentialtherapywithosimertinibontheoverallsurvivalinpatientswithegfrmutantnonsmallcelllungcancer AT isamimizushima impactofsequentialtherapywithosimertinibontheoverallsurvivalinpatientswithegfrmutantnonsmallcelllungcancer AT kanahayashi impactofsequentialtherapywithosimertinibontheoverallsurvivalinpatientswithegfrmutantnonsmallcelllungcancer AT zentaseto impactofsequentialtherapywithosimertinibontheoverallsurvivalinpatientswithegfrmutantnonsmallcelllungcancer AT kotarotokui impactofsequentialtherapywithosimertinibontheoverallsurvivalinpatientswithegfrmutantnonsmallcelllungcancer AT chihirotaka impactofsequentialtherapywithosimertinibontheoverallsurvivalinpatientswithegfrmutantnonsmallcelllungcancer AT seisukeokazawa impactofsequentialtherapywithosimertinibontheoverallsurvivalinpatientswithegfrmutantnonsmallcelllungcancer AT kentakambara impactofsequentialtherapywithosimertinibontheoverallsurvivalinpatientswithegfrmutantnonsmallcelllungcancer AT shingoimanishi impactofsequentialtherapywithosimertinibontheoverallsurvivalinpatientswithegfrmutantnonsmallcelllungcancer AT toshiromiwa impactofsequentialtherapywithosimertinibontheoverallsurvivalinpatientswithegfrmutantnonsmallcelllungcancer AT ryujihayashi impactofsequentialtherapywithosimertinibontheoverallsurvivalinpatientswithegfrmutantnonsmallcelllungcancer AT shokomatsui impactofsequentialtherapywithosimertinibontheoverallsurvivalinpatientswithegfrmutantnonsmallcelllungcancer AT kazuyukitobe impactofsequentialtherapywithosimertinibontheoverallsurvivalinpatientswithegfrmutantnonsmallcelllungcancer |